Shan Gao

This inventor holds 17 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Suzhou Ribo Life Science Company, Ltd., Suzhou Ribo Life Science Co., Ltd.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shan Gao. Retrieved from https://idiyas.com/inventor/shan-gao-mg9cfupt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 25)

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 25(Granted Patents)

Location History:

Kunshan, CN (2016 - 2024)
Suzhou, CN (2022 - 2024)

Company Filing History:

13 out of 19

Suzhou Ribo Life Science Company, Ltd.

patents

4 out of 4

Suzhou Ribo Life Science Co., Ltd.

patents

Years Active: 2016-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12624355 - DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF (2026-05-12),

2. 12590304 - NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE (2026-03-31),

3. 12577565 - NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE (2026-03-17),

4. 12540323 - NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE (2026-02-03),

5. 12497622 - NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE (2025-12-16),

6. 12496347 - NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF (2025-12-16),

7. 12428642 - Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof (2025-09-30),

8. 12274752 - Nucleic acid, composition and conjugate containing same, preparation method, and use thereof (2025-04-14),

9. 12084661 - Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof (2024-09-10),

10. 12083142 - Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof (2024-09-10),

11. 11918600 - Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof (2024-03-05),

12. 11896674 - SiRNA conjugate, preparation method therefor and use thereof (2024-02-13),

13. 11660347 - Nucleic acid, composition and conjugate containing same, preparation method, and use thereof (2023-05-30),

14. 11492620 - Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof (2022-11-08),

15. 11414665 - Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof (2022-08-16),

Title: **Innovator Spotlight: Shan Gao**

Introduction

Shan Gao is a renowned inventor based in Suzhou, China, recognized for his significant contributions to the field of molecular biology. With a portfolio of ten patents, Gao has focused his innovative efforts on developing nucleic acid technologies aimed at combating various health issues, particularly those related to viral infections. His work continues to influence the advancement of pharmaceutical compositions and therapeutic strategies.

Latest Patents

Among his latest patents, Shan Gao has developed a siRNA aimed at inhibiting the expression of the apolipoprotein C3 (ApoC3) gene. This invention includes a novel pharmaceutical composition and conjugate that leverages modified nucleotides to enhance therapeutic efficacy. Additionally, he has contributed to a siRNA formulation targeting the hepatitis B virus, again incorporating modified nucleotides in its design. Each of these formulations consists of both a sense strand and an antisense strand, designed with specific nucleotide sequences to ensure optimal performance with minimal variations from established sequences.

Career Highlights

Shan Gao is currently employed at Suzhou Ribo Life Science Company, Ltd., where he collaborates with a team of skilled professionals dedicated to pioneering advancements in life sciences. His work has played a pivotal role in progressing the understanding and treatment of genetic expression related to various diseases, showcasing his commitment to innovation in health solutions.

Collaborations

Shan Gao works alongside esteemed colleagues such as Hongyan Zhang and Daiwu Kang, contributing to the development of breakthrough technologies in molecular therapeutics. Their collective efforts have enabled significant strides in the sphere of RNA interference and its applications in medicine.

Conclusion

With a robust portfolio of patents and innovative contributions to the field of molecular biology, Shan Gao stands as a prominent figure in the realm of scientific research and development. His ongoing work at Suzhou Ribo Life Science Company, Ltd. continues to pave the way for new treatments and therapeutic strategies, making a lasting impact on healthcare and medical science.

Profile summary based on public USPTO records.